Hookipa Pharma INC Form 4 insider transactions

Malte Peters, CEO of HOOKIPA Pharma Inc., executed a sale of 25,172 shares of common stock at a weighted average price of $0.8217 per share.

HOOKIPA Pharma Inc.'s CEO, Malte Peters, sold 29,176 shares of common stock at $0.92 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.

HOOKIPA Pharma Inc.'s EVP and CFO, Mary Theresa Coelho, sold 13,609 shares of common stock at $0.92 per share to satisfy tax withholding obligations related to restricted stock unit vesting.

Mary Theresa Coelho, EVP and CFO of Hookipa Pharma Inc., reports the acquisition of restricted stock units (RSUs) that will vest over the next two years.

CEO of Hookipa Pharma, Malte Peters, reports acquisition of common stock through a restricted stock unit grant.

Director Sean A. Cassidy acquired 9,800 stock options in Hookipa Pharma Inc. on July 22, 2024.

Director Malte Peters acquired 49,000 stock options in Hookipa Pharma Inc. on June 17, 2024.

Director David Ross Kaufman acquired 49,000 stock options in Hookipa Pharma Inc. on June 17, 2024.

Director Jan van de Winkel acquired 98,000 stock options in Hookipa Pharma Inc. on June 17, 2024.

Director Julie O'Neill reports acquisition of stock options in Hookipa Pharma Inc.

Mary Theresa Coelho, a director of HOOKIPA Pharma Inc., acquired 49,000 stock options on June 17, 2024.

Director Timothy P. Reilly acquired stock options for 49,000 shares of Hookipa Pharma Inc. on June 17, 2024.

Chief Scientific Officer Klaus Orlinger reports the acquisition of stock options in Hookipa Pharma Inc.

Hookipa Pharma Inc.'s CEO, Jorn Aldag, acquired 971,400 stock options on April 15, 2024, exercisable at $0.76.

Mark Winderlich, Chief Development Officer of Hookipa Pharma Inc., acquired stock options on April 15, 2024.

Reinhard Kandera, CFO of Hookipa Pharma Inc., reports the acquisition of stock options.

Roman Necina, Chief Operations Officer of Hookipa Pharma Inc., reports acquisition of stock options.